Lupus Science and Medicine Podcast

Anti-Müllerian hormone in African- American women with SLE

Duane Peters from the Lupus Foundation of America interviews Ms Meghan Angley and Dr Sam Lim from Emory University in Georgia, and Dr Megan Clowse from Duke University in North Carolina, about infertility and reproductive injustice in African-American women with systemic lupus erythematosus.
Access the papers here:
https://lupus.bmj.com/content/7/1/e000439
https://lupus.bmj.com/content/7/1/e000455

Efficacy and safety of rituximab biosimilar in refractory lupus

Duane Peters from the Lupus Foundation of America interviews Dr Pintip Ngamjanyaporn and Dr Nantakarn Pongtarakulpanit from Mahidol University in Bangkok, Thailand, about their study on the short term efficacy and safety of rituximab biosimilar in refractory lupus.
Access the paper here: https://lupus.bmj.com/content/7/1/e000442

Metabolic syndrome in SLE patients

Duane Peters from the Lupus Foundation of America interviews Dr Diane Apostolopoulos and Dr Eric Morand from Monash Health in Australia about their study into the prevalence of metabolic syndrome in patients with SLE and the potential associations between the use of glucocorticoids and specific cardiovascular risk factors.
Access the paper here: https://lupus.bmj.com/content/7/1/e000436

Validating the use of LFA-REAL to measure disease severity in SLE

Duane Peters from the Lupus Foundation of America interviews Dr Manuel Francisco Ugarte-Gil from Peru and Dr Joan Merrill and Dr Anca Askanase from the USA about their study evaluating the use of LFA-REAL clinician-reported and patient-reported outcomes in establishing disease severity in SLE.
Access the paper here: https://lupus.bmj.com/content/7/1/e000419

ANA testing in SLE and autoimmune rheumatic diseases

Duane Peters from the Lupus Foundation of America interviews Dr May Choi and Dr Peter Schur from the Lupus Program at Brigham and Women's Hospital in Boston. They discuss the use of the ANA assay for the diagnosis and classification of systemic lupus and other autoimmune rheumatic diseases.
Access the paper here: https://lupus.bmj.com/content/7/1/e000431

Kynurenine pathway is altered in patients with SLE and associated with severe fatigue

Duane Peters of the Lupus Foundation of America talks to Elisabet Svenungsson and Helena Idborg from Karolinska Institutet about their published paper: Kynurenine pathway is altered in patients with SLE and associated with severe fatigue.
Access the paper here: http://doi.org/10.1136/lupus-2017-000254

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus

Duane Peters of the Lupus Foundation of America talks to Elisabet Svenungsson and Helena Idborg from Karolinska Institutet about their published paper:TNF-alpha and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus.
Access the paper here: http://doi.org/10.1136/lupus-2018-000260

Lupus Science & Medicine: what makes it special?

Duane Peters from the Lupus Foundation of America interviews Dr Jill Buyon, Professor of Rheumatology at New York University School of Medicine and co-Editor-in-Chief of Lupus Science & Medicine. Dr Buyon presents an overview of the journal's strengths and unique features, the editorial review process, and why authors should consider submitting their next lupus paper to LSM.
Learn more about the journal at lupus.bmj.com

Anifrolumab effects on rash and arthritis

Lupus Science & Medicine Associate Editor Professor Lars Ronnblom talks to Professor Joan T. Merrill from the Oklahoma Medical Research Foundation about her published paper: Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.
Access the paper here: https://lupus.bmj.com/content/5/1/e000284

COVID-19 Impact on people with lupus

Dr Jill Buyon, co-Editor in Chief of Lupus, Science & Medicine, explores the lessons we're learning six months into the global pandemic and the impact this is having on lupus patients, the medical landscape, and the research publishing space.